<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362632">
  <stage>Registered</stage>
  <submitdate>3/07/2012</submitdate>
  <approvaldate>4/07/2012</approvaldate>
  <actrnumber>ACTRN12612000714886</actrnumber>
  <trial_identification>
    <studytitle>Effect of vitamin D supplementation on glucose control and inflammatory response in type II diabetic patients.</studytitle>
    <scientifictitle>Effect of vitamin D supplementation on glucose control and inflammatory response in type II diabetic patients.</scientifictitle>
    <utrn>U1111-1131-8300</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type II Diabetes Mellitus</healthcondition>
    <healthcondition>Vitamin D deficiency</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 1: Vitamin D3 (Cholecalciferol) capsules.  (5000 IU/day) for 12 weeks.</interventions>
    <comparator>Arm 2: Placebo Capsules. (one capsule/day) for 12 weeks.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Changes in A1C level using serum assay.</outcome>
      <timepoint>At baseline and week 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in Homeostatic Model Assessment (HOMA) of beta cell function and insulin resistance (IR).</outcome>
      <timepoint>At baseline and week 12.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in metabolic syndrome components (blood pressure, waist circumference, body mass index, fasting blood glucose, and lipid profile)</outcome>
      <timepoint>At baseline, week 4, and week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in the level of select biomarkers of inflammation (IL-6, TNF-alpha, CRP, adiponectin, and leptin) using serum bioplex assay.</outcome>
      <timepoint>At baseline and week 12.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in 25(OH)D, and parathyroid hormone (PTH) levels using serum assay.</outcome>
      <timepoint>At baseline, week 4, and week 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes in parathyroid hormone related peptide (PTH-rP) using serum ELISA.</outcome>
      <timepoint>At baseline and week 12.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>* Adult (aged 21-75 year-old) at start of screening.

* Type II Diabetic patients.  

* A1C level (&gt; or =) 6 within the last 3 months.

* Insulin Resistance based on Homeostatic model assessment (HOMA-IR) (&gt; or =) 2 

* Serum 25-hydroxyvitamin D level (25(OH)D) level &lt; (20 ng/ml) (50 nmol/l)

* Normal kidney function (eGFR &gt; 90) using CKD-EPI formula

* On a stable oral hypoglycemic drug regimen for at least 30 days prior to screening. Those who are on thiazolidinedione should be on stable regimen for at least 6 months prior to screening.

* On stable regimen of lipid lowering drug for at least 30 days prior to screening or not on one at all.

* On stable regimen of antihypertensive drugs for at least 30 days prior to screening or not on one at all.</inclusivecriteria>
    <inclusiveminage>21</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1)History of any of the following diseases: 
           A)	Chronic kidney diseases eGFR &lt; 90
           B)	Chronic liver disease.
           C)	Congestive heart failure.
           D)	Myocardial infarction (MI) within the last 6 months.
           E)	History of cerebrovascular accident.
           F)	Hypercalcemia (serum calcium &gt; 10.2 mg/dl)
           G)	Proteinurea (&gt; 3.5 g/24 hours)
           H)	Autoimmune or inflammatory diseases [(e.g. 
               sarcoidosis, systemic lupus erythematous (SLE),
               rheumatoid arthritis (RA)].
            I)	Gastrointestinal malabsorption disorders (e.g.  
               celiac, crohns disease)
            J)	Primary parathyroid disorders.
           K)	malignancy
2)	Currently taking any of the following drugs: 
           A)	Insulin.
           B)	Activated Vitamin D analogs or nutritional vitamin  
               D agents &gt; 800 IU/day
           C)	Glucocorticoid
           D)	Antiepeleptic (e.g. phenytoin, phosphenytoin, 
               barbiturate, primidone)
           E)	Carbamezapine
           F)	Digoxin
           G)	Cholestyramine
           H)	Orlistat
3) History of gastric bypass surgery or removal of part of stomach or small intestine.
4) Pregnant or breastfeeding.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>28/11/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>22</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Saudi Arabia</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Albany College of Pharmacy and Health Sciences (ACPHS)</primarysponsorname>
    <primarysponsoraddress>Albany College of Pharmacy and Health Sciences (ACPHS) 
O'Brien Building, suite 231 
106 New Scotland Avenue 
Albany, N.Y.12208</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Albany College of Pharmacy And Health Sciences</fundingname>
      <fundingaddress>106 New Scotland Ave.
 Albany, NY 12208.</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Mohammed Al-Sofiani</sponsorname>
      <sponsoraddress>Albany College of Pharmacy and Health Sciences (ACPHS) 
O'Brien Building, suite 231 
106 New Scotland Avenue 
Albany, N.Y.12208</sponsoraddress>
      <sponsorcountry>United States of America</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Diabetes Mellitus increases both morbidity and mortality due to the long term effects of high blood sugar on kidneys, eyes, and heart. Some studies have described an important role for vitamin D in blood sugar control. In this study, our object is to detect if vitamin D supplementation in vitamin D deficient type II diabetic patients has beneficial effects on sugar control.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Institutional Review Board- King Saud University- College of Medicine</ethicname>
      <ethicaddress>P.O. Box 7805 Riyadh 11472
Kingdom of Saudi Arabia</ethicaddress>
      <ethicapprovaldate>31/10/2011</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Saudi Arabia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Institution Review Board of Albany College of Pharmacy</ethicname>
      <ethicaddress>Albany College of Pharmacy and Health Sciences (ACPHS) 
106 New Scotland Avenue 
Albany, N.Y.12208</ethicaddress>
      <ethicapprovaldate>1/03/2012</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Darius L. Mason. Pharm.D., BCPS</name>
      <address>Albany College of Pharmacy and Health Sciences (ACPHS) 
106 New Scotland Ave. 
Albany, NY 12208</address>
      <phone>+1 518 694-7449</phone>
      <fax />
      <email>Darius.Mason@acphs.edu</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>MOHAMMED AL-SOFIANI, MD</name>
      <address>Albany College of Pharmacy and Health Sciences (ACPHS) 
O'Brien Building, suite 231 
106 New Scotland Avenue 
Albany, N.Y.12208</address>
      <phone>+1 518 253-9929</phone>
      <fax />
      <email>dr_moh2008@hotmail.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>MOHAMMED AL-SOFIANI, MD</name>
      <address>Albany College of Pharmacy and Health Sciences (ACPHS) 
O'Brien Building, suite 231 
106 New Scotland Avenue 
Albany, N.Y.12208</address>
      <phone>+1 518 253-9929</phone>
      <fax />
      <email>dr_moh2008@hotmail.com</email>
      <country>United States of America</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>